MBX Biosciences, Inc. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
MBX Biosciences, Inc. (MBX) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$616.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-08-06
- MBX Biosciences, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-06-30 was -$616.00K.
- MBX Biosciences, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-03-31 was -$892.00K.
- MBX Biosciences, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-12-31 was $132.00K.
- MBX Biosciences, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-09-30 was $143.00K, a 18.18% increase year-over-year.
- MBX Biosciences, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2025 was $231.00K.
- MBX Biosciences, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was -$5.00K, a 108.77% decline from fiscal 2023.
- MBX Biosciences, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2023 was $57.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$616.00K 10-Q · filed 2026-08-06 | -$1.51M 10-Q · filed 2026-08-06 | -$1.38M derived: sum of 3 quarters · filed 2026-08-06 | -$1.23M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$892.00K 10-Q · filed 2026-08-06 | -$760.00K derived: sum of 2 quarters · filed 2026-08-06 | -$617.00K derived: sum of 3 quarters · filed 2026-08-06 | -$659.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $132.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $275.00K derived: sum of 2 quarters · filed 2026-03-12 | $233.00K derived: sum of 3 quarters · filed 2026-08-06 | $231.00K 10-K · filed 2026-03-12 |
| 2025-09-30 | $143.00K 10-Q · filed 2025-11-06 | $101.00K derived: sum of 2 quarters · filed 2026-08-06 | $99.00K 10-Q · filed 2025-11-06 | $48.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$42.00K 10-Q · filed 2026-08-06 | -$44.00K 10-Q · filed 2026-08-06 | -$95.00K derived: sum of 3 quarters · filed 2026-08-06 | $26.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$2.00K 10-Q · filed 2026-08-06 | -$53.00K derived: sum of 2 quarters · filed 2026-08-06 | $68.00K derived: sum of 3 quarters · filed 2026-08-06 | $56.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2024-12-31 | -$51.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $70.00K derived: sum of 2 quarters · filed 2026-03-12 | $58.00K derived: sum of 3 quarters · filed 2026-03-12 | -$5.00K 10-K · filed 2026-03-12 |
| 2024-09-30 | $121.00K 10-Q · filed 2025-11-06 | $109.00K derived: sum of 2 quarters · filed 2025-11-06 | $46.00K 10-Q · filed 2025-11-06 | $97.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$12.00K 10-Q · filed 2025-11-06 | -$75.00K 10-Q · filed 2025-08-07 | -$24.00K derived: sum of 3 quarters · filed 2025-11-06 | -$15.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-03-31 | -$63.00K 10-Q · filed 2025-11-06 | -$12.00K derived: sum of 2 quarters · filed 2025-11-06 | -$3.00K derived: sum of 3 quarters · filed 2025-11-06 | -$7.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2023-12-31 | $51.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $60.00K derived: sum of 2 quarters · filed 2025-03-17 | $56.00K derived: sum of 3 quarters · filed 2025-03-17 | $57.00K 10-K · filed 2025-03-17 |
| 2023-09-30 | $9.00K 10-Q · filed 2024-11-07 | $5.00K derived: sum of 2 quarters · filed 2024-11-07 | $6.00K 10-Q · filed 2024-11-07 | |
| 2023-06-30 | -$4.00K 10-Q · filed 2024-11-07 | -$3.00K derived: sum of 2 quarters · filed 2024-11-07 | ||
| 2023-03-31 | $1.00K 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |